Ping Wang1, Yang Song2, Michael D Weir2, Jinyu Sun2, Liang Zhao3, Carl G Simon4, Hockin H K Xu5. 1. Biomaterials & Tissue Engineering Division, Department of Endodontics, Prosthodontics and Operative Dentistry, University of Maryland Dental School, Baltimore, MD 21201, USA; State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China. 2. Biomaterials & Tissue Engineering Division, Department of Endodontics, Prosthodontics and Operative Dentistry, University of Maryland Dental School, Baltimore, MD 21201, USA. 3. Biomaterials & Tissue Engineering Division, Department of Endodontics, Prosthodontics and Operative Dentistry, University of Maryland Dental School, Baltimore, MD 21201, USA; Department of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. Electronic address: lzhaonf@126.com. 4. Biosystems and Biomaterials Division, National Institute of Standards & Technology, 100 Bureau Drive, Gaithersburg, MD, 20899, USA. 5. Biomaterials & Tissue Engineering Division, Department of Endodontics, Prosthodontics and Operative Dentistry, University of Maryland Dental School, Baltimore, MD 21201, USA; Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Mechanical Engineering Department, University of Maryland Baltimore County, Baltimore County, MD 21250, USA. Electronic address: hxu@umaryland.edu.
Abstract
OBJECTIVES: Calcium phosphate cements (CPCs) are promising for dental and craniofacial repairs. The objectives of this study were to: (1) develop an injectable cell delivery system based on encapsulation of induced pluripotent stem cell-derived mesenchymal stem cells (iPSMSCs) in microbeads; (2) develop a novel tissue engineered construct by dispersing iPSMSC-microbeads in CPC to investigate bone regeneration in an animal model for the first time. METHODS: iPSMSCs were pre-osteoinduced for 2 weeks (OS-iPSMSCs), or transduced with bone morphogenetic protein-2 (BMP2-iPSMSCs). Cells were encapsulated in fast-degradable alginate microbeads. Microbeads were mixed with CPC paste and filled into cranial defects in nude rats. Four groups were tested: (1) CPC-microbeads without cells (CPC control); (2) CPC-microbeads-iPSMSCs (CPC-iPSMSCs); (3) CPC-microbeads-OS-iPSMSCs (CPC-OS-iPSMSCs); (4) CPC-microbeads-BMP2-iPSMSCs (CPC-BMP2-iPSMSCs). RESULTS: Cells maintained good viability inside microbeads after injection. The microbeads were able to release the cells which had more than 10-fold increase in live cell density from 1 to 14 days. The cells exhibited up-regulation of osteogenic markers and deposition of minerals. In vivo, new bone area fraction (mean±SD; n=5) for CPC-iPSMSCs group was (22.5±7.6)%. New bone area fractions were (38.9±18.4)% and (44.7±22.8)% for CPC-OS-iPSMSCs group and CPC-BMP2-iPSMSCs group, respectively, 2-3 times the (15.6±11.2)% in CPC control at 12 weeks (p<0.05). Cell-CPC constructs accelerated scaffold resorption, with CPC-BMP2-iPSMSCs having remaining scaffold material that was 7-fold less than CPC control. SIGNIFICANCE: Novel injectable CPC-microbead-cell constructs promoted bone regeneration, with OS-iPSMSCs and BMP2-iPSMSCs having 2-3 fold the new bone of CPC control. Cell delivery accelerated scaffold resorption, with CPC-BMP2-iPSMSC having remaining scaffold material that was 7-fold less than CPC control. Therefore, CPC-microbead-iPSMSC is a promising injectable material for orthopedic, dental and craniofacial bone regenerations. Published by Elsevier Ltd.
OBJECTIVES:Calcium phosphate cements (CPCs) are promising for dental and craniofacial repairs. The objectives of this study were to: (1) develop an injectable cell delivery system based on encapsulation of induced pluripotent stem cell-derived mesenchymal stem cells (iPSMSCs) in microbeads; (2) develop a novel tissue engineered construct by dispersing iPSMSC-microbeads in CPC to investigate bone regeneration in an animal model for the first time. METHODS: iPSMSCs were pre-osteoinduced for 2 weeks (OS-iPSMSCs), or transduced with bone morphogenetic protein-2 (BMP2-iPSMSCs). Cells were encapsulated in fast-degradable alginate microbeads. Microbeads were mixed with CPC paste and filled into cranial defects in nude rats. Four groups were tested: (1) CPC-microbeads without cells (CPC control); (2) CPC-microbeads-iPSMSCs (CPC-iPSMSCs); (3) CPC-microbeads-OS-iPSMSCs (CPC-OS-iPSMSCs); (4) CPC-microbeads-BMP2-iPSMSCs (CPC-BMP2-iPSMSCs). RESULTS: Cells maintained good viability inside microbeads after injection. The microbeads were able to release the cells which had more than 10-fold increase in live cell density from 1 to 14 days. The cells exhibited up-regulation of osteogenic markers and deposition of minerals. In vivo, new bone area fraction (mean±SD; n=5) for CPC-iPSMSCs group was (22.5±7.6)%. New bone area fractions were (38.9±18.4)% and (44.7±22.8)% for CPC-OS-iPSMSCs group and CPC-BMP2-iPSMSCs group, respectively, 2-3 times the (15.6±11.2)% in CPC control at 12 weeks (p<0.05). Cell-CPC constructs accelerated scaffold resorption, with CPC-BMP2-iPSMSCs having remaining scaffold material that was 7-fold less than CPC control. SIGNIFICANCE: Novel injectable CPC-microbead-cell constructs promoted bone regeneration, with OS-iPSMSCs and BMP2-iPSMSCs having 2-3 fold the new bone of CPC control. Cell delivery accelerated scaffold resorption, with CPC-BMP2-iPSMSC having remaining scaffold material that was 7-fold less than CPC control. Therefore, CPC-microbead-iPSMSC is a promising injectable material for orthopedic, dental and craniofacial bone regenerations. Published by Elsevier Ltd.
Entities:
Keywords:
Alginate microbeads; Animal studies; Bone tissue engineering; Calcium phosphate cement; Human induced pluripotent stem cells; Injectable
Authors: Kang I Ko; Leila S Coimbra; Chen Tian; Jazia Alblowi; Rayyan A Kayal; Thomas A Einhorn; Louis C Gerstenfeld; Robert J Pignolo; Dana T Graves Journal: Diabetologia Date: 2015-01-07 Impact factor: 10.122
Authors: Pengyan Qiao; Juan Wang; Qiufei Xie; Fangfang Li; Limin Dong; Tao Xu Journal: Mater Sci Eng C Mater Biol Appl Date: 2013-07-24 Impact factor: 7.328
Authors: Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng Journal: Cell Res Date: 2011-01-18 Impact factor: 25.617
Authors: Ping Wang; Tao Ma; Dong Guo; Kevin Hu; Yan Shu; Hockin H K Xu; Abraham Schneider Journal: J Tissue Eng Regen Med Date: 2017-08-11 Impact factor: 3.963
Authors: Xian Liu; Wenchuan Chen; Chi Zhang; Wahwah Thein-Han; Kevin Hu; Mark A Reynolds; Chongyun Bao; Ping Wang; Liang Zhao; Hockin H K Xu Journal: Tissue Eng Part A Date: 2017-03-10 Impact factor: 3.845
Authors: Gengtao Qiu; Hansen Wu; Mingguang Huang; Tao Ma; Abraham Schneider; Thomas W Oates; Michael D Weir; Hockin H K Xu; Liang Zhao Journal: Mater Sci Eng C Mater Biol Appl Date: 2021-07-10
Authors: Lin Wang; Chi Zhang; Chunyan Li; Michael D Weir; Ping Wang; Mark A Reynolds; Liang Zhao; Hockin H K Xu Journal: Mater Sci Eng C Mater Biol Appl Date: 2016-08-10 Impact factor: 7.328
Authors: Sundus Iftikhar; Noureen Jahanzeb; Mehvish Saleem; Shafiq Ur Rehman; Jukka Pekka Matinlinna; Abdul Samad Khan Journal: Saudi Dent J Date: 2021-01-14